serpin family B member 10Genealiases: PI-10 · PI10
Q-omics provides the consensus-scored SERPINB10 profile across patient tissues and cancer cell-line models. SERPINB10 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SERPINB10 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, SERPINB10 protein abundance shows 26,233 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BLCA, KIRC, and PDAC as cancer lineages where SERPINB10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINB10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINB10 survival associations across molecular data types. SERPINB10 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINB10 RNA expression–survival associations across cancer types. High SERPINB10 expression shows unfavorable associations in BLCA, ACC, UVM and SCLC, but favorable associations in MESO and CESC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SERPINB10 RNA expression.
This table summarizes SERPINB10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SERPINB10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINB10 shows lower tumor expression in KIRC, KIRP, LUAD and HNSC and higher tumor expression in BRCA and LUSC. The KIRC box plot shows higher SERPINB10 RNA expression in normal versus tumor tissue (log2 FC = −0.043, t-test p < 0.001).
This table shows molecular features associated with SERPINB10 in patient tissues and cancer cell lines. In patient samples, SERPINB10 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINB10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
